Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

LowFloatScanner_ Oct. 24 at 8:34 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $NKTR $VWAV $ARTV $BTW.X recent movers

0 · Reply

Mangokitty83 Oct. 24 at 8:06 PM

$NKTR

0 · Reply

LiquidThetaLEAPS Oct. 24 at 7:44 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NKTR Current Share Price: $63.10 Contracts: $NKTR January 15, 2027 $65 Calls Scale in: $22.50- $27.50 Scale out: $35.00-$45.00 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

noofnoof1 Oct. 24 at 5:35 PM

$NKTR Twitter user @unemon1 offered an interesting theory that $LLY might be in the acquisition process. Link to DD below. Thoughts? https://unemon.com/ResearchEasy/202510_NKTR/20251022_NKTR_LLY.html

2 · Reply

Jgarcapital Oct. 24 at 4:11 PM

$NKTR initiated a position. We riding to $100+

0 · Reply

lovemytattoos Oct. 24 at 3:15 PM

$NKTR I expect to see many more attempts from LLY to try to avert a run-up before the sale. Much harder to buy a company and get shareholder approval when it’s already priced over $100/share.

0 · Reply

lovemytattoos Oct. 24 at 2:49 PM

$NKTR The LLY PR is uneventful and feels like a desperate attempt to gain footing in their negotiation. I’m further convinced of a buyout. Also thinking it will be December after Alopecia readout. Expect $300-$500. Hopefully closer to the $500. Trust me you will wake up to a headline on this.

0 · Reply

nesanmano Oct. 24 at 2:31 PM

$NKTR will we close at 65

0 · Reply

MoMoneyNoProb Oct. 24 at 2:26 PM

$NKTR Why is this SOB down?

0 · Reply

FinABAT Oct. 24 at 1:49 PM

$NKTR whats a fair price?

1 · Reply

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 2:31 PM EDT - 5 weeks ago

Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Sep 18, 2025, 8:45 AM EDT - 5 weeks ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 4, 2025, 2:52 PM EDT - 7 weeks ago

What's Going On With Nektar Therapeutics Stock On Thursday?

Sep 3, 2025, 7:00 PM EDT - 7 weeks ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 8, 2025, 7:48 PM EDT - 2 months ago

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:15 PM EDT - 2 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 3 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 3 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 4 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 4 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 4 months ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 4 months ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 4 months ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 4 months ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 4 months ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 4 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 4 months ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 4 months ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 4 months ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 5 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 6 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 6 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 6 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 7 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 8 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 8 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 8 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 8 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 8 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 8 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 9 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 10 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 11 months ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 1 year ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nov 14, 2024, 9:11 AM EST - 1 year ago

Multiple Catalysts Ahead For Nektar Therapeutics

Nov 8, 2024, 12:21 AM EST - 1 year ago

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 10:15 AM EST - 1 year ago

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 6:00 PM EST - 1 year ago

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 1:44 PM EST - 1 year ago

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nov 4, 2024, 8:30 AM EST - 1 year ago

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Oct 31, 2024, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Oct 17, 2024, 12:07 PM EDT - 1 year ago

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Sep 25, 2024, 3:30 AM EDT - 1 year ago

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Sep 3, 2024, 9:00 AM EDT - 1 year ago

Nektar Management to Present at Upcoming Investor Conferences

Aug 10, 2024, 9:04 AM EDT - 1 year ago

Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

LowFloatScanner_ Oct. 24 at 8:34 PM

0 · Reply

Mangokitty83 Oct. 24 at 8:06 PM

$NKTR

0 · Reply

LiquidThetaLEAPS Oct. 24 at 7:44 PM

0 · Reply

noofnoof1 Oct. 24 at 5:35 PM

$NKTR Twitter user @unemon1 offered an interesting theory that $LLY might be in the acquisition process. Link to DD below. Thoughts? https://unemon.com/ResearchEasy/202510_NKTR/20251022_NKTR_LLY.html

2 · Reply

Jgarcapital Oct. 24 at 4:11 PM

$NKTR initiated a position. We riding to $100+

0 · Reply

lovemytattoos Oct. 24 at 3:15 PM

$NKTR I expect to see many more attempts from LLY to try to avert a run-up before the sale. Much harder to buy a company and get shareholder approval when it’s already priced over $100/share.

0 · Reply

lovemytattoos Oct. 24 at 2:49 PM

0 · Reply

nesanmano Oct. 24 at 2:31 PM

$NKTR will we close at 65

0 · Reply

MoMoneyNoProb Oct. 24 at 2:26 PM

$NKTR Why is this SOB down?

0 · Reply

FinABAT Oct. 24 at 1:49 PM

$NKTR whats a fair price?

1 · Reply

OptionRunners Oct. 24 at 1:49 PM

$NKTR $LLY takeover rumors again

0 · Reply

jerrybe5000 Oct. 24 at 12:28 PM

$NKTR is the LLY press release a big negative for NKTR? Trying to understand the dynamics of their respective drugs…

2 · Reply

Martin85_ Oct. 23 at 2:40 PM

$NKTR lets go 70 $

1 · Reply

Yimmiedd Oct. 23 at 1:59 PM

$NKTR

0 · Reply

StockConsultant Oct. 23 at 1:56 PM

$NKTR Nektar Therapeutics stock breakout

0 · Reply

WiseGuyInvestin Oct. 23 at 1:51 PM

$NKTR BREAKOUT ALERT!!! Congrats boys, you’re gonna be rich 💰💰💰

0 · Reply

dayfornight99 Oct. 23 at 1:46 PM

$NKTR Boom

1 · Reply

nesanmano Oct. 23 at 11:58 AM

$NKTR give me 63

0 · Reply

masonat Oct. 23 at 11:32 AM

$NKTR Nemluvio already at$1B annualized very early into launch. Rezpeg demonstrably more effective than Nemluvio.

0 · Reply

smartkarma Oct. 23 at 6:01 AM

$NKTR | Nektar Therapeutics Gains Momentum As Eli Lilly Buyout Buzz Explodes! "Nektar Therapeutics is back in Wall Street’s spotlight after reports and social media speculation suggested that pharmaceutical heavyweight Eli..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/nektar-therapeutics-gains-momentum-as-eli-lilly-buyout-buzz-explodes

0 · Reply

Lets_Go_Brndn Oct. 22 at 7:54 PM

$NKTR New position today. Will be $70 by Friday. After they present late breaking abstract will be $150. No doubter. Get it now.

2 · Reply

TonyK666 Oct. 22 at 1:12 PM

$NKTR

0 · Reply

Market Cap	1.21B
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	1,355,100
Avg Vol	1,095,722
Day's Range	N/A - N/A
Shares Out	19.02M
Stochastic %K	53%
Beta	1.18
Analysts	Strong Sell
Price Target	$93.86